Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults
- PMID: 22876085
- PMCID: PMC3411227
Item in Clipboard
Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults
P T.
2012 May.
No abstract available
Figures
Structural formula of fidaxomicin. (From Dificid prescribing information.17)
Similar articles
-
A case report of successful management of clostridium difficile colitis with antegrade Fidaxomicin through a mucous fistula obviating the need for subtotal colectomy.Int J Surg Case Rep. 2018;42:79-81. doi: 10.1016/j.ijscr.2017.11.042. Epub 2017 Nov 27. Int J Surg Case Rep. 2018. PMID: 29227855 Free PMC article.
-
Stability and recovery of DIFICID(®) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube.Drugs R D. 2014 Dec;14(4):309-14. doi: 10.1007/s40268-014-0067-3. Drugs R D. 2014. PMID: 25424419 Free PMC article.
-
Role of fidaxomicin for the treatment of Clostridium difficile infection.J Pharm Pract. 2013 Oct;26(5):491-7. doi: 10.1177/0897190013499526. J Pharm Pract. 2013. PMID: 24064437
-
Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S110-5. doi: 10.1093/cid/cis390. Clin Infect Dis. 2012. PMID: 22752858 Free PMC article. Review.
-
Fidaxomicin for the treatment of Clostridium difficile infections.Ann Pharmacother. 2012 Feb;46(2):219-28. doi: 10.1345/aph.1Q481. Epub 2012 Feb 7. Ann Pharmacother. 2012. PMID: 22318930 Review.
Cited by
-
Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility.PLoS One. 2020 Nov 9;15(11):e0241903. doi: 10.1371/journal.pone.0241903. eCollection 2020. PLoS One. 2020. PMID: 33166349 Free PMC article.
-
In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.Sci Rep. 2021 Mar 29;11(1):7093. doi: 10.1038/s41598-021-86595-3. Sci Rep. 2021. PMID: 33782498 Free PMC article.
-
Current and Ongoing Developments in Targeting Clostridioides difficile Infection and Recurrence.Microorganisms. 2024 Jun 15;12(6):1206. doi: 10.3390/microorganisms12061206. Microorganisms. 2024. PMID: 38930588 Free PMC article. Review.
-
Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile.mSphere. 2024 Jul 30;9(7):e0027324. doi: 10.1128/msphere.00273-24. Epub 2024 Jun 28. mSphere. 2024. PMID: 38940508 Free PMC article.
-
Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.Cureus. 2018 Jun 11;10(6):e2778. doi: 10.7759/cureus.2778. Cureus. 2018. PMID: 30112254 Free PMC article. Review.
References
-
- Drekonja DM, Butler M, MacDonald R, et al. Comparative ef fectiveness of Clostridium difficile treatments: A systematic review. Ann Intern Med. 2011;155:839–847. - PubMed
-
- Gerding DDN, Johnson S, Peterson LR, et al. Clostridium difficile–associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16:459–477. - PubMed
-
- Reinke CM, Messick CR. Update on Clostridium difficile–induced colitis (parts 1 and 2) Am J Hosp Pharm. 1994;51:1771–1781. 1892–1901. - PubMed
-
- Fekety R. Guidelines for the diagnosis and management of Clostridium difficile–associated diarrhea and colitis. Am J Gastroenterol. 1997;92:739–750. - PubMed
-
- American Society of Health-System Pharmacists Pharmacy News. Fidaxomicin approved for C. difficile infections. May 31, 2011. Available at: www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=3549. Accessed February 29, 2012. - PubMed
LinkOut - more resources
Full Text Sources